Buprenorphine Hydrochloride And Naloxone Hydrochloride Dihydrate Tablet
Product Images NDC 16729-549

HCI stands for Human-Computer Interaction. It is an interdisciplinary field of study that focuses on the design and evaluation of computer systems and other interactive technologies that are easy to use and enhance the human experience. This field draws on knowledge and techniques from computer science, psychology, sociology, design, and other related disciplines to develop technology that is accessible, efficient, and engaging for people to use.*

This medication is Buprenorphine and Naloxone, distributed by Accord Healthcare. It should be stored between 20 to 25°C. Buprenorphine and Naloxone sublingual tablets should be kept out of reach of children, and accidental ingestion by minors may require emergency medical care. The medication guide should be given to the patient, and each tablet contains 2 mg of Buprenorphine Hydrochloride USP and 0.5 mg of Naloxone Hydrochloride Dihydrate USP. The dosage information is not available.*

This is a description of buprenorphine and naloxone sublingual tablets, which are used for treating opioid addiction. The tablets are dispensed in a tight, light-resistant container with child-resistant closure, and it is important to keep them out of children's reach. The medication guide should be given to each patient by the pharmacist. The tablets are manufactured by WES Pharma Inc in Westminster, MD and distributed by Accord Healthcare, Inc in Durham, NC. The tablets contain 8 mg of buprenorphine hydrochloride USP and 2 mg of naloxone hydrochloride dihydrate USP. Dosage should be determined by a healthcare provider, and accidental ingestion by children should be treated as a medical emergency. The storage temperature for the tablets should be 20° to 25°C.*